Read by QxMD icon Read

falcon trial

Jan Franko, Qian Shi, Jeffrey P Meyers, Timothy S Maughan, Richard A Adams, Matthew T Seymour, Leonard Saltz, Cornelis J A Punt, Miriam Koopman, Christophe Tournigand, Niall C Tebbutt, Eduardo Diaz-Rubio, John Souglakos, Alfredo Falcone, Benoist Chibaudel, Volker Heinemann, Joseph Moen, Aimery De Gramont, Daniel J Sargent, Axel Grothey
BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008...
October 12, 2016: Lancet Oncology
Caroline J Falconer, Aitor Rovira, John A King, Paul Gilbert, Angus Antley, Pasco Fearon, Neil Ralph, Mel Slater, Chris R Brewin
BACKGROUND: Self-criticism is a ubiquitous feature of psychopathology and can be combatted by increasing levels of self-compassion. However, some patients are resistant to self-compassion. AIMS: To investigate whether the effects of self-identification with virtual bodies within immersive virtual reality could be exploited to increase self-compassion in patients with depression. METHOD: We developed an 8-minute scenario in which 15 patients practised delivering compassion in one virtual body and then experienced receiving it from themselves in another virtual body...
January 2016: BJPsych Open
Rachel S Kerr, Sharon Love, Eva Segelov, Elaine Johnstone, Beverly Falcon, Peter Hewett, Andrew Weaver, David Church, Claire Scudder, Sarah Pearson, Patrick Julier, Francesco Pezzella, Ian Tomlinson, Enric Domingo, David J Kerr
BACKGROUND: Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. METHODS: For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals in seven countries, we recruited patients aged 18 years or older with WHO performance status scores of 0 or 1 who had undergone potentially curative surgery for histologically proven stage III or high-risk stage II colorectal cancer...
September 19, 2016: Lancet Oncology
R-D Hofheinz, U Ronellenfitsch, S Kubicka, A Falcone, I Burkholder, U T Hacker
Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression...
2016: Gastroenterology Research and Practice
James Loughead, Mary Falcone, E Paul Wileyto, Benjamin Albelda, Janet Audrain-McGovern, Wen Cao, Matthew M Kurtz, Ruben C Gur, Caryn Lerman
BACKGROUND AND AIMS: Deficits in cognitive function are observed during nicotine withdrawal and present a challenge to successful smoking cessation. This clinical trial evaluated a cognitive exercise training (CT) program to improve smoking cessation rates. METHODS: Adult treatment-seeking smokers (n=213) were randomized to receive nicotine patch therapy and 12 weeks of either computerized CT or computerized relaxation (control) training. Smoking status was biochemically verified at the end of treatment and 6-month follow-up...
August 27, 2016: Drug and Alcohol Dependence
Chiara Caparello, Laura L Meijer, Ingrid Garajova, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti
Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule...
August 21, 2016: World Journal of Gastroenterology: WJG
Rebecca L Flyckt, Ruth M Farrell, Uma C Perni, Andreas G Tzakis, Tommaso Falcone
This commentary endeavors to share our practical experience in developing and implementing the first uterine transplant clinical trial in the United States. Uterine transplant is a promising novel treatment for uterine factor infertility. After reported successful live births after uterine transplant in Sweden, research teams around the world are either embarking on or are considering the development of uterine transplant protocols. Our observations on the applied rather than theoretical aspects of uterine transplantation research in human subjects are detailed in this article...
October 2016: Obstetrics and Gynecology
Jacqueline van den Bos, Rutger M Schols, Misha D Luyer, Ronald M van Dam, Alexander L Vahrmeijer, Wilhelmus J Meijerink, Paul D Gobardhan, Gooitzen M van Dam, Nicole D Bouvy, Laurents P S Stassen
INTRODUCTION: Misidentification of the extrahepatic bile duct anatomy during laparoscopic cholecystectomy (LC) is the main cause of bile duct injury. Easier intraoperative recognition of the biliary anatomy may be accomplished by using near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG). Promising results were reported for successful intraoperative identification of the extrahepatic bile ducts compared to conventional laparoscopic imaging...
August 26, 2016: BMJ Open
Teresa Di Desidero, Lisa Derosa, Luca Galli, Paola Orlandi, Andrea Fontana, Anna Fioravanti, Riccardo Marconcini, Mario Giorgi, Beatrice Campi, Alessandro Saba, Sara Lucchesi, Renato Felipetto, Romano Danesi, Giulio Francia, Giacomo Allegrini, Alfredo Falcone, Guido Bocci
The aim of the present study was to evaluate clinical activity, and the pharmacodynamic and pharmacokinetic profiles, of oral metronomic vinorelbine (VNR) plus dexamethasone (DEX) in metastatic castration-resistant prostate cancer (mCRPC) patients. Fourty-one patients (92 % chemotherapy-resistant) received 30 mg/day VNR p.o. thrice a week plus 1 mg/day DEX p.o. until disease progression. Plasma soluble B cell antigen 7 homolog 3 (sB7-H3), vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1), were measured by ELISA...
August 24, 2016: Investigational New Drugs
Francesca Poggio, Matteo Lambertini, Eva Blondeaux, Marina Vaglica, Alessia Levaggi, Paolo Pronzato, Lucia Del Mastro
INTRODUCTION: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. AREAS COVERED: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications...
September 2016: Expert Review of Clinical Pharmacology
Javier Castrodeza, Ignacio J Amat-Santos, Myriam Blanco, Carlos Cortes, Javier Tobar, Irene Martin-Morquecho, Javier López, Salvatore Di Stefano, Paol Rojas, Luis H Varela-Falcon, Itziar Gomez, Jose A San Roman
BACKGROUND: Recently, the use of transcatheter aortic valve implantation (TAVI) in intermediate-low risk patients has been evaluated in the PARTNER II randomized trial. However, in the last years, this therapy has been employed in this scenario with underreported results, as compared to surgical aortic valve replacement (SAVR). METHODS: We enrolled 362 consecutive patients with severe symptomatic aortic stenosis and intermediate-low surgical risk (logEuroSCORE < 20%), treated in our center with TAVI (103 patients) or single SAVR (259 patients) between 2009 and 2014...
July 21, 2016: Cardiology Journal
Paolo Marchetti, Annalisa Milano, Chiara D'Antonio, Adriana Romiti, Rosa Falcone, Michela Roberto, Stefano Fais
The acidification of extracellular compartment represents a conceivable mechanism of drug resistance in malignant cells. In addition, it has been reported to drive proliferation and promote invasion and metastasis. Experimental evidence has shown that proton pump inhibitors can counteract tumor acidification and restore sensitivity to anticancer drugs. Moreover, early clinical data have supported the role of proton pump inhibitors in anticancer treatments. Metronomic capecitabine has demonstrated beneficial effects as salvage chemotherapy for heavily pretreated or frail patients with gastrointestinal cancer...
June 23, 2016: Clinical Colorectal Cancer
Marco Falcone, David Paterson
During the last decade infections caused by MDR Gram-negative bacteria (GNB) have become increasingly prevalent. Because of their high morbidity and mortality rates, these infections constitute a serious threat to public health worldwide. Ceftazidime/avibactam is a new approved agent combining ceftazidime and a novel β-lactamase inhibitor with activity against various β-lactamases produced by MDR GNB. Avibactam has a spectrum of inhibition of class A and C β-lactamases, including ESBLs, AmpC and Klebsiella pneumoniae carbapenemase (KPC) enzymes...
October 2016: Journal of Antimicrobial Chemotherapy
Christel Gentil, Caroline Le Guiner, Sestina Falcone, Jean-Yves Hogrel, Cécile Peccate, Stéphanie Lorain, Sofia Benkhelifa-Ziyyat, Lydie Guigand, Marie Montus, Laurent Servais, Thomas Voit, France Piétri-Rouxel
At present, the clinically most advanced strategy to treat Duchenne muscular dystrophy (DMD) is the exon-skipping strategy. Whereas antisense oligonucleotide-based clinical trials are underway for DMD, it is essential to determine the dystrophin restoration threshold needed to ensure improvement of muscle physiology at the molecular level. A preclinical trial has been conducted in golden retriever muscular dystrophy (GRMD) dogs treated in a forelimb by locoregional delivery of rAAV8-U7snRNA to promote exon skipping on the canine dystrophin messenger...
September 2016: Human Gene Therapy
Nancy A Carney, Gustavo J Petroni, Silvia B Luján, Nicolás M Ballarini, Gabriela A Faguaga, Hugo E M du Coudray, Amy E Huddleston, Gloria M Baggio, Juan M Becerra, Leonardo O Busso, Sureyya S Dikmen, Roberto Falcone, Mirta E García, Osvaldo R González Carrillo, Paula L Medici, Marta B Quaglino, Carina A Randisi, Silvia S Sáenz, Nancy R Temkin, Elida E Vanella
OBJECTIVE: To develop, in partnership with families of children with traumatic brain injury, a postdischarge intervention that is effective, simple, and sustainable. DESIGN: Randomized Controlled Trial. SETTING: Seven Level 1 Pediatric Trauma Centers in Argentina. PATIENTS: Persons less than 19 years of age admitted to one of the study hospitals with a diagnosis of severe, moderate, or complicated mild traumatic brain injury and were discharged alive...
July 2016: Pediatric Critical Care Medicine
J Martínez Pérez, A Falcón González, I Sánchez Simón, A Cervera, M Alonso García, M J Flor Oncala, I Gallego Jiménez, P Maíquez, L Jiménez González-Serna, J Corral
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
Satoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Stefan Stremitzer, Satoshi Matsusaka, Martin D Berger, Anish Parekh, Jordan D West, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Chiara Cremolini, Alfredo Falcone, Volker Heinemann, R William DePaolo, Heinz-Josef Lenz
The purpose of this study was to evaluate the clinical significance of single-nucleotide polymorphisms in TLR1, TLR2, TLR6, and TAK1 in patients with metastatic colorectal cancer (mCRC). We genotyped 9 SNPs of TLR1, TLR2, TLR6, and TAK1 in mCRC patients treated with first-line FOLFIRI (combination therapy of irinotecan, 5-fluorouracil, and folinic acid) plus bevacizumab, using a discovery cohort (TRIBE trial, n = 228) and a validation cohort (FIRE-3 trial, n = 297), and analyzed for the association with response rate (RR), progression-free survival (PFS), and overall survival (OS)...
July 2016: Molecular Cancer Therapeutics
Michela Roberto, Adriana Romiti, Concetta Elisa Onesti, Angelo Zullo, Rosa Falcone, Paolo Marchetti
Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also...
July 2016: Expert Review of Anticancer Therapy
Caterina Vivaldi, Chiara Caparello, Gianna Musettini, Giulia Pasquini, Silvia Catanese, Lorenzo Fornaro, Monica Lencioni, Alfredo Falcone, Enrico Vasile
FOLFIRINOX is a standard first-line treatment for advanced pancreatic cancer (aPC). The Gruppo Oncologico Nord Ovest (GONO) FOLFOXIRI regimen demonstrated efficacy in metastatic colorectal cancer. We aimed to evaluate activity and tolerability of FOLFOXIRI regimen in patients with aPC and to explore putative prognostic factors. One hundred thirty-seven consecutive aPC patients were treated with FOLFOXIRI in our institution between 2008 and 2014. Clinical, laboratory and pathological data were collected and their association with activity, progression free survival (PFS) and overall survival (OS) was investigated...
August 15, 2016: International Journal of Cancer. Journal International du Cancer
Angélica Saraí Jiménez-Osorio, Wylly Ramsés García-Niño, Susana González-Reyes, Alejandra Elizabeth Álvarez-Mejía, Sebastián Guerra-León, Jonathan Salazar-Segovia, Ilse Falcón, Héctor Montes de Oca-Solano, Magdalena Madero, José Pedraza-Chaverri
OBJECTIVE: Chronic kidney disease (CKD) is a worldwide public health problem, and proteinuria may accelerate the progression of CKD, being oxidative stress a common mechanism in nondiabetic or diabetic proteinuric kidney disease. This study was designed to evaluate the effect of the dietary supplementation with curcumin (CUR) on the redox status and the nuclear factor erythroid 2-related factor 2 (Nrf2) activation in patients with nondiabetic or diabetic proteinuric CKD. DESIGN: Randomized double-blind placebo-controlled clinical trial...
July 2016: Journal of Renal Nutrition
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"